018 | BSA nanoparticles containing collagenases and doxorubicin to enhance therapeutic efficacy in 3D models of solid tumor
Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · 31.03.2026 · 99 (s1)
DOI: 10.4081/jbr.2026.15270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale, online erschienen am 31.03.2026. Verfasst von Società Italiana di Biologia Sperimentale. Die Arbeit nennt 1 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Solid tumors are characterized by a complex acidic microenvironment dominated by a dense collagen-rich extracellular matrix (ECM), that act as a major physical barrier to drug penetration, thereby limiting therapeutic efficacy. In this context, strategies that combine ECM remodeling with anticancer drugs represent a promising approach for the cancer treatment [1]. This project aimed to develop bovine serum albumin (BSA)–based nanoparticles loaded with the anticancer drug doxorubicin (BSA–DOX NPs) exhibiting pH-responsive behavior, and to evaluate their therapeutic potential in synergy with BSA-based collagenases nanoparticles designed to remodel the ECM and enhance drug uptake in solid tumors. The BSA–DOX nanoparticles displayed spherical morphology and uniform nanoscale dimensions, achieving a drug loading efficiency of approximately 50%. Under acidic conditions, they exhibit pronounced aggregation, suggesting that this behavior could promote selective intratumoral retention, offering a mechanism that may enhance therapeutic outcomes while reducing off-target effects. In primary breast cancer spheroids, pretreatment with free ultrapure recombinant collagenases significantly increased doxorubicin cytotoxicity, particularly when delivered via BSA–DOX nanoparticles, highlighting a synergistic effect obtained by ECM degradation and nanoparticles conjugated with chemotherapies. Since ultrapure recombinant collagenases (COL H and COL G) are characterized by low immunocompatibility due to their bacterial origin, BSA NPs encapsulating COLH and COLG were developed. Thermal crosslinking strategy enabled the production of BSA-COLH and BSA-COLG NPs with nanoscale dimensions, spherical morphology and good dispersion, preserving enzymatic activity, as shown by zymography assay. Overall, these results indicate that the combination of pH-responsive BSA nanoparticles loaded with doxorubicin and thermally crosslinked collagenase-containing BSA nanoparticles could represents a promising strategy for improving drug delivery and specificity in solid tumors by overcoming stromal barriers and enhancing intratumoral drug accumulation.
Zitieren
APA
Sperimentale, S. I. D. B. (2026). 018 | BSA nanoparticles containing collagenases and doxorubicin to enhance therapeutic efficacy in 3D models of solid tumor. Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale, 99(s1). https://doi.org/10.4081/jbr.2026.15270
Vancouver
Sperimentale SIDB. 018 | BSA nanoparticles containing collagenases and doxorubicin to enhance therapeutic efficacy in 3D models of solid tumor. Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale. 2026;99(s1). doi:10.4081/jbr.2026.15270
BibTeX
@article{Sperimentale2026,
author = {Sperimentale, Società Italiana di Biologia},
title = {018 | BSA nanoparticles containing collagenases and doxorubicin to enhance therapeutic efficacy in 3D models of solid tumor},
journal = {Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale},
year = {2026},
volume = {99},
number = {s1},
doi = {10.4081/jbr.2026.15270}
}
EUVIMED